beta

PHAT

Phathom Pharmaceuticals Inc

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

phathom pharmaceuticals, inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. the company has the rights in the united states, europe, and canada to vonoprazan, a potassium-competitive acid blocker (p-cab) that blocks acid secretion in the stomach. it is also developing vonoprazan, which is in phase iii clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of helicobacter pylori infection. the company was incorporated in 2018 and is based in buffalo grove, illinois.

Market Cap: 557 Million

Primary Exchange: NASDAQ

Website: phathompharma.com

Shares Outstanding: 57.3 Million

Float: 0

Dividend: 0.0 (0.0%)

Beta: 1.0270348651273695

Sector: Manufacturing

Industry: Medicinal and Botanical Manufacturing

Ethical Flags

Longest drawdown: 393 trading days

From: 2020-06-08 To: 2024-03-07

Lowest Point:

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud